Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | CYP3A5 | P20815 | 4/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.52 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29363322 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP3A5GPR119PLA2G7MGLL | |
| SCHEMBL15093706 | 0.87 | CYP3A4 (0.71) | CYP3A4CYP3A5GPR119PLA2G7MGLL | |
| SCHEMBL31071488 | 0.87 | CYP3A4 (0.71) | CYP3A4CYP3A5GPR119PLA2G7MGLL | |
| SCHEMBL1852622 | 0.86 | GLS (0.57) | CYP3A4CYP3A5GPR119MGLLGLS | |
| SCHEMBL210120 | 0.86 | CYP3A4 (0.61) | CYP3A4CYP3A5GPR119PLA2G7MGLL | |
| SCHEMBL22365058 | 0.83 | CYP3A4 (0.52) | CYP3A4CYP3A5GPR119PLA2G7MGLL | |
| SCHEMBL14035283 | 0.83 | CYP3A4 (0.58) | CYP3A4CYP3A5GPR119PLA2G7MGLL | |
| SCHEMBL20818634 | 0.83 | CYP3A4 (0.58) | CYP3A4CYP3A5GPR119PLA2G7MGLL | |
| SCHEMBL30476445 | 0.83 | CYP3A4 (0.58) | CYP3A4CYP3A5GPR119PLA2G7MGLL | |
| SCHEMBL1240443 | 0.80 | KCNA5 (0.64) | CYP3A4CYP3A5GPR119PLA2G7MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12630808-B2 | Modified archaeal family b polymerases | Singular Genomics Systems, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | AUCKLAND UNISERVICES LTD (NZ) | 2026-04-02 | — | — | US | disclosed |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4677087-A1 | NOVEL TREATMENTS FOR OCULAR DISORDERS | Glaukos Corporation (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250381270-A1 | ISOLATING ACTIVE T-CELL CARS FROM BULK TRANSDUCED HUMAN T-CELLS | UNIV CALIFORNIA (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250352508-A1 | PREVENTION AND TREATMENT OF POST-ACUTE INFECTION SYNDROMES | INFLAMMX THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250353926-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | ENLAZA THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2019204768-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-24 | — | — | WO | disclosed |
| US-10420843-B2 | Compositions and methods relating to salts of specialized pro-resolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2019-09-24 | — | — | US | disclosed |
| WO-2019178248-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019173760-A1 | BIOREACTIVE COMPOSITIONS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-12 | — | — | WO | disclosed |
| EP-3454907-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION | Thetis Pharmaceuticals LLC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10130719-B2 | Compositions and methods relating to salts of specialized pro-resolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180200375-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS | THETIS PHARMACEUTICALS LLC (US) | 2018-07-19 | — | — | US | disclosed |
| WO-2018097999-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20180110751-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS | THETIS PHARMACEUTICALS LLC | 2018-04-26 | — | — | US | disclosed |
| WO-2017210604-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION | THETIS PHARMACEUTICALS LLC (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10420843-B2 | Compositions and methods relating to salts of specialized pro-resolving mediators | PTGER1, PTGER4, PTGER2 | CYP3A4 1333/4885CYP3A5 1648/4885GPR119 899/4885 |
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | P2RX7, NLRP3, PYCARD | CYP3A4 2376/4885CYP3A5 3219/4885GPR119 1901/4885 |
| US-20250352508-A1 | PREVENTION AND TREATMENT OF POST-ACUTE INFECTION SYNDROMES | NLRP3, GJA1, PYCARD | CYP3A4 3187/4885CYP3A5 2558/4885GPR119 2666/4885 |
| US-12630808-B2 | Modified archaeal family b polymerases | SSU72, POLB, POLQ | CYP3A4 4157/4885CYP3A5 3367/4885GPR119 4260/4885 |
| US-20180200375-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS | ALOX15B, LTB4R2, ALOX5 | CYP3A4 1352/4885CYP3A5 1149/4885GPR119 449/4885 |
| US-20250381270-A1 | ISOLATING ACTIVE T-CELL CARS FROM BULK TRANSDUCED HUMAN T-CELLS | PBK, CD4, ICOS | CYP3A4 4727/4885CYP3A5 4665/4885GPR119 2829/4885 |
| US-20250353926-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | FCGR3B, FCGR2A, CD22 | CYP3A4 4836/4885CYP3A5 4644/4885GPR119 4058/4885 |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | POLB, POLM, POLRMT | CYP3A4 1356/4885CYP3A5 3108/4885GPR119 4602/4885 |
| US-20180110751-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS | ALOX15B, LTB4R2, ALOX5 | CYP3A4 1352/4885CYP3A5 1149/4885GPR119 449/4885 |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | DNMT3A, POLB, POLM | CYP3A4 2935/4885CYP3A5 3729/4885GPR119 4639/4885 |
| US-10130719-B2 | Compositions and methods relating to salts of specialized pro-resolving mediators | ALOX5, ALOX15, ALOX12 | CYP3A4 3818/4885CYP3A5 2681/4885GPR119 1975/4885 |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | ALOX15, ALOX12, PTGES | CYP3A4 3658/4885CYP3A5 2893/4885GPR119 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.